Remus PharmaceuticalsNSE:REMUS -0.89%53 Days Inventory is 41.27 as of Mar. 2026, which is 31% above its 10-year median of 31.41. GuruFocus rates NSE:REMUS with a GF Score™ of 53/100 and a GF Value™ of ₹2,071.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 115 Medical Distribution companies, Remus Pharmaceuticals ranks better than 68.7% on this metric.
The historical rank and industry rank for Remus Pharmaceuticals's Days Inventory or its related term are showing as below:
NSE:REMUS'
s Days Inventory Range Over the Past 10 Years
Min: 22.63 Med: 31.41 Max: 48.56
Current: 37.56
During the past 7 years, Remus Pharmaceuticals's highest Days Inventory was 48.56. The lowest was 22.63. And the median was 31.41.
NSE:REMUS's Days Inventory is ranked better than 68.7% of 115
companies
in the Medical Distribution industry
Industry Median: 57.26
vs NSE:REMUS: 37.56
Inventory Turnover measures how fast the company turns over its inventory within a year.
Remus Pharmaceuticals's Inventory Turnover for the
six
months ended in Mar. 2026 was 4.42.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Remus Pharmaceuticals's Inventory-to-Revenue for the
six
months ended in Mar. 2026 was 0.20.
Remus Pharmaceuticals (NSE:REMUS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Remus Pharmaceuticals's Inventory Turnover for the
six
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Remus Pharmaceuticals's Inventory to Revenue for the
six
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Remus Pharmaceuticals Days Inventory Related Terms
Remus Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Remus Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:REMUS vs MCK, CAH, COR: Days Inventory Comparison
For the Medical Distribution subindustry, Remus Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Remus Pharmaceuticals Days Inventory vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Remus Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Remus Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Remus Pharmaceuticals (NSE:REMUS) has a Days Inventory of 41.27 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Remus Pharmaceuticals and its competitors. This is 31% above median its historical median of 31.41. Over the past decade, Remus Pharmaceuticals' Days Inventory has ranged from 22.63 to 48.56. According to the industry distribution chart, Remus Pharmaceuticals ranks #36 out of 115 companies in the Medical Distribution industry, placing it in the top 31.3%.
Is Remus Pharmaceuticals' Days Inventory too high?
Remus Pharmaceuticals' current Days Inventory of 41.27 is 31% above median its 10-year median of 31.41. Over the past 10 years, this metric has ranged from a low of 22.63 to a high of 48.56. The Medical Distribution industry median Days Inventory is 57.26. Remus Pharmaceuticals' value of 41.27 is 27.9% below this industry median. Based on the distribution chart, Remus Pharmaceuticals ranks #36 out of 115 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Remus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Remus Pharmaceuticals' Days Inventory compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Remus Pharmaceuticals ranks #36 out of 115 companies for Days Inventory. This puts Remus Pharmaceuticals in the upper half of its industry. The industry median Days Inventory is 57.26. Remus Pharmaceuticals' value of 41.27 is 27.9% below this benchmark. Historically, Remus Pharmaceuticals' own Days Inventory has ranged from 22.63 to 48.56 over the past decade. While the company's 10-year median is 31.41 vs. the industry median of 57.26, Remus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Distribution company?
The median Days Inventory among Medical Distribution companies is 57.26, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Remus Pharmaceuticals's current Days Inventory of 41.27 is 27.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Remus Pharmaceuticals and its competitors. For the Medical Distribution industry, the median Days Inventory is 57.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Remus Pharmaceuticals's current Days Inventory is 41.27, which is 31% above median its own 10-year median of 31.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Remus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Remus Pharmaceuticals (NSE:REMUS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹2,071.36, compared to a current price of ₹780.00 — trading 62.3% below its estimated fair value. The current Days Inventory is 41.27, which is 31% above median its 10-year median of 31.41 and 27.9% below the Medical Distribution industry median of 57.26. Remus Pharmaceuticals' overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Remus Pharmaceuticals (NSE:REMUS), the current Days Inventory is 41.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Remus Pharmaceuticals (NSE:REMUS) Overvalued in 2026?
Based on GuruFocus' analysis, Remus Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹780.00 is trading 62.3% below its estimated GF Value™ of ₹2,071.36.
GuruFocus considers Remus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for NSE:REMUS:
Days Inventory: 41.27 (31% above median its 10-year median of 31.41)
GF Value™: ₹2,071.36 vs. price of ₹780.00 (62.3% below fair value)
Industry Position: 27.9% below the Medical Distribution median (#36 of 115)
No single metric tells the full story. See the NSE:REMUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.
53GF Score
Get the complete analysis for NSE:REMUS
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:REMUS has been successfully added to your 
